NCT01037231已完成2 期
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria.
OxThera3 个研究点 分布在 3 个国家目标入组 36 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 3
- 主要终点
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24
研究概览
简要总结
The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent (as applicable for the age of the subject)
- •Male or female subjects ≥ 2 years of age
- •A mean urinary oxalate excretion of > 1.0 mmol/1.73m2/day from eligible urine collections performed during screening.
- •A diagnosis of PH I or PH II by one of the following:
- •Liver biopsy confirmation of deficient liver specific peroxisomal alanine-glyoxylate aminotransferase, (AGT) or mislocalization of AGT from peroxisomes to mitochondria (PH I) or deficient glyoxylate reductase/hydroxypyruvate reductase (GRHPR) activity (PH II)
- •Homozygosity or compound heterozygosity for a known mutation in the causative genes for PH I and PH II.
- •Increased glycolate excretion for PH I or increased L-glycerate excretion for PH II.
- •Subjects receiving pyridoxine must be receiving a stable dose for at least 3 months prior to entry into the study and must remain on the stable dose during the study. Subjects not receiving pyridoxine at study entry must be willing to refrain from initiating pyridoxine during study participation.
- •Renal function defined as an estimated GFR ≥ 40 ml/min normalized to 1.73m2 body surface area, or a creatinine clearance of ≥ 40 ml/min normalized to 1.73m2 body surface area.
排除标准
- •Inability to collect two complete 24-hour urine samples. Each urine collection will be evaluated for completeness based on the urine acceptance criteria outlined in section 11.
- •Subjects diagnosed as PH I who are pyridoxine naïve.
- •Subjects that have undergone transplantation (solid organ or bone marrow).
- •The existence of secondary hyperoxaluria, e.g. chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome.
- •Current systemic (oral, IM, IV) antibiotic use or received systemic antibiotics within 14 days of study enrolment.
- •History of a recurrent infection requiring >2 courses of systemic antibiotics in the past 6 months, or chronic antimicrobial suppression.
- •Subjects who require immune suppressive therapy (including prednisone > 10mg daily for more than 2 weeks).
- •Current treatment with a separate ascorbic acid preparation. Ascorbic acid up to 250mg/day as a component of a multivitamin formulation is not excluded.
- •Known hypersensitivity to esomeprazol (or any of the other ingredients of this medicine), or to any other proton pump inhibitor medicine. (Nexium contraindication)
- •Concomitant treatment with atazanavir. (Nexium contraindication)
- •Women of child-bearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of OxabactTM and must agree to continue using such precautions during the clinical study.
- •Presence of a medical condition that the Principal Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures. Note: Subjects from correctional facilities or asylums and subjects who are mentally handicapped are not to be included in the study.
- •Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to randomization or not willing to forego other forms of investigational treatment during this study.
研究组 & 干预措施
Oxabact (tm)
Experimental
干预措施: Oxalobacter formigenes (Biological)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24
时间窗: 24 weeks
次要结局
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 8(8 weeks)
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 in subsets of subjects defined by baseline urinary oxalate level, above and below median at screening(24 weeks)
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 in subsets of subjects defined by concomitant vitamin B6 therapy and no vitamin B6 therapy, in PH type I(24 weeks)
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 in subsets of subjects defined by eGFR of ≥90 mL/min/1.73m2 and < 90 mL/min/1.73m2(24 weeks)
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 in subsets of subjects defined by PH Type I and PH Type II(24 weeks)
- Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 in subsets of subjects defined by age below 18 and age 18 or above(24 weeks)
- Percentage of subjects who have ≥20% reduction from Baseline urinary oxalate at Week 24(24 weeks)
- Percentage change in plasma oxalate levels(24 weeks)
- Frequency of Stone Events (i.e. nephrolithiasis or markers thereof)(24 weeks)
- Correlation between percentage change in plasma oxalate levels and percentage change in urinary oxalate levels, from Baseline to Week 24(24 weeks)
- Adverse events (AEs), hematology, clinical chemistry, urinalysis.(24 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary HyperoxaluriaPrimary HyperoxaluriaNCT02012985OxThera28
已完成
2 期
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria PatientsPrimary HyperoxaluriaNCT00638703OxThera43
已完成
2 期
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on DialysisPrimary HyperoxaluriaNCT02000219OxThera12
已完成
不适用
Oxygen Insufflation To Reduce Postoperative Abscess In Laparoscopic AppendectomyPostoperative AbscessNCT01531413Chang, Steve S., M.D.100
已完成
不适用
Oxalobacter Formigenes Colonization and Urinary Oxalate ExcretionCalcium Oxalate UrolithiasisNCT03752684University of Alabama at Birmingham26